Danish pharmaceutical giant Novo Nordisk has partnered with OpenAI to embed advanced AI technology throughout its drug development pipeline, from early research to manufacturing and commercial operations. This collaboration aims to accelerate drug discovery, analyze complex datasets, and reduce time-to-market for new therapies, with full AI integration targeted by the end of 2026. The partnership also includes workforce upskilling in AI literacy. This move reflects a broader industry trend where AI is becoming central to pharmaceutical R&D, although regulatory approvals still depend on traditional clinical and review processes.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
